Endovastec(SH:688016) Sou Hu Cai Jing·2025-09-06 22:01Core Viewpoint - The company, Xinmai Medical, has shown significant growth in revenue and profit, with a focus on expanding its product offerings and international market presence. Financial Performance - For the reporting period, the company achieved operating revenue of 714 million yuan and a net profit attributable to shareholders of 315 million yuan, with basic earnings per share of 2.55 yuan [1][4] - The company plans to distribute a cash dividend of 13.00 yuan per 10 shares, totaling 157 million yuan [1] Product Development and Approvals - Several products have made breakthroughs in the first half of 2025, including the Cratos branched aortic stent system, which has been approved for clinical use in China [1] - The company has a total of 31 products available globally, with 5 receiving CE certification and 9 entering special review procedures for innovative medical devices in China [2] Market Expansion - The Cratos branched stent is priced under 100,000 yuan and has exceeded promotional expectations, with clinical studies initiated in Europe [3] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total sales, driven by the integration of Lombard data and growth in international markets [3][4] Share Buyback Program - The company is conducting a second phase of share repurchase, with a budget of 100 million to 200 million yuan, aimed at employee stock ownership plans or equity incentives [5] - As of August 31, 2025, the company has repurchased 1,228,743 shares, representing 1.00% of total share capital, with a total expenditure of approximately 129 million yuan [5]